ArticleMolecular cancer therapeutics2015

CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans.

Grant Eilers et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.